Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H20N2O2 |
Molecular Weight | 260.3315 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1
InChI
InChIKey=FVNFBBAOMBJTST-UHFFFAOYSA-N
InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)
Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma. Fenspiride is marketed under the brand names Eurespal, Pneumorel, SYRESP, Oxofen and others. Erespal (fenspiride) is a drug with a bronchodilator and spasmolytic effect, which is often used in the complex therapy of bronchial asthma. Fenspiride has a clinically proven ability to increase the activity of the cilia of the bronchial ciliated epithelium, normalize the secretion of the bronchi and reduce its viscosity. Effectively removes bronchial obstruction, restores pulmonary gas exchange. Inhibits the metabolism of arachidonic acid, in parallel blocking histamine H1-receptors, since it is histamine that stimulates the chemical reactions of the transformation of arachidonic acid into the final metabolites-factors of inflammation. Reduces the production of other mediators of inflammation - serotonin and bradykinin.
It blocks α-adrenergic receptors, the activation of which increases the secretion of bronchial glands. The complex effect of fenspiride reduces the pathological effect of a number of factors that promote hypersecretion of anti-inflammatory substances and cause obstruction of the bronchial tree. Has a pronounced antispasmodic and myotropic effect.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: http://o-t-c.co.uk/eurespal-buy-online |
|||
Target ID: P16599 Gene ID: 103694380|||24835 Gene Symbol: Tnf Target Organism: Rattus norvegicus (Rat) |
|||
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9489859 |
4.16 null [pIC50] | ||
Target ID: CHEMBL2094125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9489859 |
3.44 null [pIC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Eurespal Approved UseIndications:
Rinofaringitis, laryngitis
— otitis, sinusitis
— rinotraheobronhit
— bronchitis
— bronchial asthma (maintenance therapy)
respiratory effects in measles, pertussis and influenza (syrup). |
|||
Primary | Eurespal Approved UseIndications:
Rinofaringitis, laryngitis
— otitis, sinusitis
— rinotraheobronhit
— bronchitis
— bronchial asthma (maintenance therapy)
respiratory effects in measles, pertussis and influenza (syrup). |
PubMed
Title | Date | PubMed |
---|---|---|
Detection of fenspiride and identification of in vivo metabolites in horse body fluids by capillary gas chromatography-mass spectrometry: administration, biotransformation and urinary excretion after a single oral dose. | 2002 Feb 5 |
|
[Fenspiride-a new alternative on the therapy of obstructive lung disease]. | 2003 Apr-Jun |
|
[The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis]. | 2005 Aug |
|
Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease. | 2006 |
|
[The effectiveness of fenspiride in the treatment of patients with chronic obstructive pulmonary disease]. | 2007 |
|
[Pathogenetic therapy for inflammatory diseases of the middle ear]. | 2009 |
Sample Use Guides
Tablets: One tablet (80 mg) twice-thrice a day. The maximum dose for a daily intake is 240 mg (3 tablets).
Syrup: For 45-90 milliliters (3-6 tablespoons, respectively) per day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9163640
Curator's Comment: Fenspiride (10(-7)-10(-5) M) inhibited the histamine H1 receptor-induced Ca2+ increase in a lung epithelial cell line. Fenspiride (10(-5) M) abolished both phases of histamine-induced arachidonic acid release. https://www.ncbi.nlm.nih.gov/pubmed/9652346
Fenspiride (10(-6) to 10(-4) M) inhibited the nonadrenergic, noncholinergic (NANC) component of the contraction of the guinea-pig isolated main bronchus induced by EFS. Fenspiride significantly affected contractions induced by exogenously added substance P or [Nle10]-NKA(4-10) only at concentrations higher than 10(-3) M. In the guinea-pig perfused lung, fenspiride inhibited low pH- but not capsaicin-evoked release of CGRP. At higher concentrations (10(-4) M to 3x10(-4) M) fenspiride exhibited a significant inhibitory effect both on the cholinergic component of contractile response induced by EFS in the guinea-pig isolated main bronchus and on exogenously added acetylcholine.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03BX01
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
||
|
WHO-ATC |
R03BX01
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
||
|
WHO-VATC |
QR03DX03
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
||
|
WHO-ATC |
R03DX03
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL576127
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
DTXSID4023048
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
100000081488
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
5053-06-5
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
3344
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
SUB07596MIG
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
1163
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
FENSPIRIDE
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
DB08979
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
2577
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
m5296
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | Merck Index | ||
|
C80880
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
4335
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | RxNorm | ||
|
C084775
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
225-751-3
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY | |||
|
S983QC7HKM
Created by
admin on Fri Dec 15 15:51:39 UTC 2023 , Edited by admin on Fri Dec 15 15:51:39 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)